Reneuron Share Discussion Threads

[letmepass] 03/10/2019 11:52

Back to 120s

[investordave] 03/10/2019 11:48

Staggeringly, the share price is now now by over 40% since yesterday's announcement. Having read and reread the RNS in detail, this seems like a massive overreaction or am I missing something?

[rrb] 03/10/2019 11:47

company has not communicated this well at all. But naysayers are out in force and this thing is going to stay under pressure until the shorters/sellers on news is done. I would think these are the levels we need to find support. If not, could drift back to low 100s.

[dickbush] 03/10/2019 11:29

Thanks rrp for that link.

I read it as a pretty fair summation except that the company said at the start of this second trial that less improvement was expected from the newer patients treated because they started from a higher level of vision. Though this is mentioned, I believe it deserves greater emphasis and simply demonstrates that the worse the condition, the better the improvement. If, with greater numbers of patients, this proves to be the case then the market for its stem cells will be smaller but certainly not insignificant.

Still, in the current stockmarket environment, falling like a stone, the shares may continue under pressure. Call me crazy but, given the avoidance of potential patients with severely damaged retinas, the results are good enough for success in the make or break Phase 2b trials with a larger number of patients. Note that “Sanofi and Regeneron’s age-related macular degeneration blockbuster, Eylea, has been linked with 8-11-letter improvements.” That's much lower than the numbers Reneuron achieved ex the two patients with very damaged retinas.

[s1zematters] 03/10/2019 11:28

It's thought that RP is hereditary and genetically motivated.
However, the data on (DHA) docosahexaenoic acid usage did seem to example slowing down of the vision loss and degeneration of the retina of Retinitis pigmentosa regardless.

Anyhow, of the above ,it's not a cure ; i was just ventilating the point that there are various treatments to RP to Phill, who stated there were none!
Again, its the results (lack off) of the treatments rather than the lack of effort in trying out various treatments

[small crow] 03/10/2019 11:06

Trouble is DHA deficiency may well be a metabolic problem rather than a dietary problem:

"The reason for the reduced level of DHA in rod OS of animals with inherited retinal degeneration is not known. However, the fatty acid composition of the rod OS of these animals suggests that the synthesis of DHA-containing glycerolipids is downregulated in retinas of animals with inherited retinal degenerations."

Also, some of the enhanced dietary studies of the effect of fatty acids on retina health take place over timespans of years, and any results are still arguable. This is analogous to saying there are lots of small lifestyle changes we can do to improve heart health, but it's still useful to have stents as a final solution .... to keep us alive. Or, to spell it out in simple language, if my eyesight was deteriorating I suspect I would like a more rapid solution than a possible dietary solution sold by Gwyneth Paltrow. Not sure why you are googling so hard to depress this price, although I have my suspicions.

[s1zematters] 03/10/2019 10:39

He never specified AMD or RP ?

That said, your comment on RP is not strictly speaking correct.
There have been various treatments , it's more a question of results of the said treatments rather than lack of them.

for example.
(DHA) docosahexaenoic acid that if found in fish along with high dose of Vitamin A have in previous studies exampled improvement and drop off in decline in cone ERG amplitudes, vision loss and degeneration of the retina of Retinitis pigmentosa sufferers.
RP vision flaws are down to photoreceptor degeneration by apoptosis.

[philh75] 03/10/2019 09:02

Also Eylea is for wet AMD, not RP! No treatments for RP on the market currently!

[s1zematters] 03/10/2019 09:00

Will it bounce from the 190p line? maybe, but will any bounce hold, I'm doubtful!


s1zematters - 02 Oct 2019 - 11:06:54 - 7151 of 7245 ReNeuron - a leading, clinical-stage stem cell business - RENE
gapdown to 190 looks like a death star tractor beam here ... aimho.

[rrb] 03/10/2019 08:11

Eylea range is 8-11 letters so, excluding those with vision loss, >17 letter improvement is positive.

Clearly, we need more longitudinal data. BUT, the shares are ridiculously cheap here.

[s1zematters] 03/10/2019 07:52

EYLEA is still available, this offers a circa 11 letter improvement , It also does not involve detachment of the retina. Eylea is administered by injection into the eye, that said, It can cause retinal detachment as a side effect!

[wigwammer] 03/10/2019 07:46

The data suggests the efficacy is strongest among patients in the more mature stage of disease with lowest baseline readings. This does not limit the size of the market - because without treatment and ongoing deterioration - every RP patient will ultimately be in this category. Judging by the posts put out - the company needs to be clearer about what surgical related vision loss means. It appears many here are assuming it means permanent blindness, as opposed to a temporary loss or reattachment of retina required. Two quite different levels of risk. At a ph2a stage - they are in the process of learning. I have little doubt that the data garnered over the last year has derisked the project and added significant value to it. They were close to achieving a deal last year and i suspect the prospects now are significantly better. GLA :)

[rrb] 03/10/2019 07:17

£65m market cap. The treatment is effective in patients who tolerated it. The extent of the efficacy is not clear yet. There are no other treatments. Very simple.

[eggy6198] 03/10/2019 06:50

Mr Hellebø blamed the two patients with vision loss, who he said “lost a lot of letters”, for dragging the result down. Excluding these two subjects gave a 17.8-letter mean improvement over baseline

[eggy6198] 03/10/2019 06:46

This style of reporting is very poor at best at worst worrying as looks like a job is being done. Rene make some great points about the results

[bigspuds] 03/10/2019 00:30

In short, still a ways to go.......unfortunately

[rrb] 02/10/2019 22:36

Good summary. Some nuances to the data, explained here. Overall I think the results not as good as some hoped for but still clear potential. key question is if it’s enough to attract a partner

[ken chung] 02/10/2019 22:35

Enjoy the drop.

[ken chung] 02/10/2019 22:34

Lemmings and mushrooms only.


The title says it all really:

"No revenues, no approvals, rising salaries and loads of dilution".

And its only taken a decade!!!

50p soon.

Lemmings and mushrooms only.

[wigwammer] 02/10/2019 20:48

Small correction. It is 2 months to 6 months data that we have, not 4 to 6. Conclusion the same - the latest data strongly suggests the efficacy of 2 of the 3 initial candidates is strong and growing. ATB :)

[algernon2] 02/10/2019 20:30

We are all squabling over the interpretation of the data set.
This should have been made totally unnecessary by the way Reneuron presented any figures in the RNS.
Good or bad or indifferent this is certainly a textbook example of how not to give a presentation or an RNS.
Any negativity could have been tempered by Rene adding comments and explanations throughout the day from themselves or the 2 good Doctors ; but regretfully they have chosen not to explain or elucidate.
That is why we are all in this quandry and the shareprice so far down on the day.
Maybe tomorrow they will make ammends.
Here's hoping.
Good luck to us all.

[wigwammer] 02/10/2019 20:21

Kingpin/PDT. I can only restate the data and you can make your own mind up. Last update, mean letter improvement from baseline was 22.7 letters for the 3 candidates at 4 months. At 6 months, that jumps to 28.7 letters. That figure is highly suggestive that - using the latest available data - two of the three candidates continue to show strong and improving efficacy.

[king1pin2] 02/10/2019 20:10

Not sure that you are correct wigwammer , all 3 of the initial candidates have made very good progress. The ones after that had a different baseline in vision so we perhaps would have expected less spectacular results but have still made progress that rene are happy with. Perhaps the biggest worry is the 2 who lost sight.
Just my understanding of a rubbish rns so not 100% sure i am right.

[pdt] 02/10/2019 20:03

The problem is that the patient treated for longest is showing improvement of 12 letters at the 9 month stage. At the 4 month stage he was showing a 21 letter improvement. It is only one patient but does this mean that success fades away over time and will patients be back to effectively where they started at 12 months?

Although there is the possibility of retreating there is risk of procedural failure and cost issues of a temporary benefit. I believe they quoted the FDA looking at 15 letters representing success. And being an invasive treatment there is a limit to retreatment.

So as Wigwammer states 2 out of 3 are showing impressive efficacy at 6 months but will that fade away by month 12??

If I have misunderstood the data please let me know. More time needed for more data and a bigger sample size needed to be sure. But it is concerning and I sold out today.

[wigwammer] 02/10/2019 20:00

Some premium weirdo would rather tick the point down than discuss it. Think I know which saddo it is. They frequently get things totally wrong :)